Loading…

Efficacy of combined bland embolization and chemoembolization for huge (≥10 cm) hepatocellular carcinoma

To assess the efficacy of combined therapy involving bland transarterial embolization using gelatin sponge particles (bland GS-TAE) followed by transarterial chemoembolization using lipiodol mixed with anticancer agents and GS particles (Lip-TACE) to reduce the adverse events and increase the therap...

Full description

Saved in:
Bibliographic Details
Published in:Minimally invasive therapy and allied technologies 2020-02, Vol.30 (4), p.221-228
Main Authors: Hidaka, Teruyuki, Anai, Hiroshi, Sakaguchi, Hiroshi, Sueyoshi, Satoru, Tanaka, Toshihiro, Yamamoto, Kiyosei, Morimoto, Kengo, Nishiofuku, Hideyuki, Maeda, Shinsaku, Nagata, Takeshi, Kichikawa, Kimihiko
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c552t-bf3a030fcbe2cd97d55976a727e892d6830318b96a16e5537de0a81ef81ad1c33
cites cdi_FETCH-LOGICAL-c552t-bf3a030fcbe2cd97d55976a727e892d6830318b96a16e5537de0a81ef81ad1c33
container_end_page 228
container_issue 4
container_start_page 221
container_title Minimally invasive therapy and allied technologies
container_volume 30
creator Hidaka, Teruyuki
Anai, Hiroshi
Sakaguchi, Hiroshi
Sueyoshi, Satoru
Tanaka, Toshihiro
Yamamoto, Kiyosei
Morimoto, Kengo
Nishiofuku, Hideyuki
Maeda, Shinsaku
Nagata, Takeshi
Kichikawa, Kimihiko
description To assess the efficacy of combined therapy involving bland transarterial embolization using gelatin sponge particles (bland GS-TAE) followed by transarterial chemoembolization using lipiodol mixed with anticancer agents and GS particles (Lip-TACE) to reduce the adverse events and increase the therapeutic effect of Lip-TACE in the treatment of huge (≥10 cm) hepatocellular carcinoma (HCC). Twenty-one consecutive patients with huge HCCs (≥10 cm in diameter) were enrolled in this study. First, bland GS-TAE was performed to reduce the tumor volume, and then Lip-TACE was performed to control the remaining tumor at intervals of around three weeks. Tumor response, survival, and adverse events of this combined therapy were assessed. The tumor response was assessed three months after combined TACE, with complete response in 38.1% and partial response in 57.1% of cases. Severe adverse events were seen in two patients, acute cholecystitis and tumor rupture. The median survival time was 2.7 years, and the one-, two-, three-, and five-year overall survival rates were 76.2%, 66.7%, 42.9%, and 25.0%, respectively. Combined therapy involving bland GS-TAE followed by Lip-TACE can be performed safety and may improve survival in patients with huge HCCs.
doi_str_mv 10.1080/13645706.2020.1725580
format article
fullrecord <record><control><sourceid>proquest_infor</sourceid><recordid>TN_cdi_proquest_miscellaneous_2352632242</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2352632242</sourcerecordid><originalsourceid>FETCH-LOGICAL-c552t-bf3a030fcbe2cd97d55976a727e892d6830318b96a16e5537de0a81ef81ad1c33</originalsourceid><addsrcrecordid>eNp9kLtOHDEUhi0EAgJ5hCCXUAzxZTyXDoSAICGlgdo640vWyB4v9ozQpkrLg_BiPAkz2QWJhuoc_frORR9CPyg5paQhPymvSlGT6pQRNkU1E6IhW2h_ykXBWk63__dlMUN76FvOD4QwKnizi_Y4I5yWdbmP_KW1ToFa4WixiqFzvdG489BrbEIXvfsLg4s9ngO1MCF-Sm1MeDH-Mfj49fmFktd_zyqc4IVZwhCV8X70kLCCpFwfAxyiHQs-m--beoDury7vLn4Vt7-vby7ObwslBBuKznIgnFjVGaZ0W2sh2rqCmtWmaZmuGj5933RtBbQyQvBaGwINNbahoKni_AAdr_cuU3wcTR5kcHl-B3oTxywZF6zijJVsQsUaVSnmnIyVy-QCpJWkRM6i5btoOYuWG9HT3NHmxNgFoz-m3s1OwNkacP0kKcBTTF7LAVY-JpugVy5L_vWNN3mdjyY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2352632242</pqid></control><display><type>article</type><title>Efficacy of combined bland embolization and chemoembolization for huge (≥10 cm) hepatocellular carcinoma</title><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Hidaka, Teruyuki ; Anai, Hiroshi ; Sakaguchi, Hiroshi ; Sueyoshi, Satoru ; Tanaka, Toshihiro ; Yamamoto, Kiyosei ; Morimoto, Kengo ; Nishiofuku, Hideyuki ; Maeda, Shinsaku ; Nagata, Takeshi ; Kichikawa, Kimihiko</creator><creatorcontrib>Hidaka, Teruyuki ; Anai, Hiroshi ; Sakaguchi, Hiroshi ; Sueyoshi, Satoru ; Tanaka, Toshihiro ; Yamamoto, Kiyosei ; Morimoto, Kengo ; Nishiofuku, Hideyuki ; Maeda, Shinsaku ; Nagata, Takeshi ; Kichikawa, Kimihiko</creatorcontrib><description>To assess the efficacy of combined therapy involving bland transarterial embolization using gelatin sponge particles (bland GS-TAE) followed by transarterial chemoembolization using lipiodol mixed with anticancer agents and GS particles (Lip-TACE) to reduce the adverse events and increase the therapeutic effect of Lip-TACE in the treatment of huge (≥10 cm) hepatocellular carcinoma (HCC). Twenty-one consecutive patients with huge HCCs (≥10 cm in diameter) were enrolled in this study. First, bland GS-TAE was performed to reduce the tumor volume, and then Lip-TACE was performed to control the remaining tumor at intervals of around three weeks. Tumor response, survival, and adverse events of this combined therapy were assessed. The tumor response was assessed three months after combined TACE, with complete response in 38.1% and partial response in 57.1% of cases. Severe adverse events were seen in two patients, acute cholecystitis and tumor rupture. The median survival time was 2.7 years, and the one-, two-, three-, and five-year overall survival rates were 76.2%, 66.7%, 42.9%, and 25.0%, respectively. Combined therapy involving bland GS-TAE followed by Lip-TACE can be performed safety and may improve survival in patients with huge HCCs.</description><identifier>ISSN: 1364-5706</identifier><identifier>EISSN: 1365-2931</identifier><identifier>DOI: 10.1080/13645706.2020.1725580</identifier><identifier>PMID: 32031474</identifier><language>eng</language><publisher>England: Taylor &amp; Francis</publisher><subject>bland embolization ; huge hepatocellular carcinoma ; transarterial chemoembolization</subject><ispartof>Minimally invasive therapy and allied technologies, 2020-02, Vol.30 (4), p.221-228</ispartof><rights>2020 Society of Medical Innovation and Technology 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c552t-bf3a030fcbe2cd97d55976a727e892d6830318b96a16e5537de0a81ef81ad1c33</citedby><cites>FETCH-LOGICAL-c552t-bf3a030fcbe2cd97d55976a727e892d6830318b96a16e5537de0a81ef81ad1c33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27900,27901</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32031474$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hidaka, Teruyuki</creatorcontrib><creatorcontrib>Anai, Hiroshi</creatorcontrib><creatorcontrib>Sakaguchi, Hiroshi</creatorcontrib><creatorcontrib>Sueyoshi, Satoru</creatorcontrib><creatorcontrib>Tanaka, Toshihiro</creatorcontrib><creatorcontrib>Yamamoto, Kiyosei</creatorcontrib><creatorcontrib>Morimoto, Kengo</creatorcontrib><creatorcontrib>Nishiofuku, Hideyuki</creatorcontrib><creatorcontrib>Maeda, Shinsaku</creatorcontrib><creatorcontrib>Nagata, Takeshi</creatorcontrib><creatorcontrib>Kichikawa, Kimihiko</creatorcontrib><title>Efficacy of combined bland embolization and chemoembolization for huge (≥10 cm) hepatocellular carcinoma</title><title>Minimally invasive therapy and allied technologies</title><addtitle>Minim Invasive Ther Allied Technol</addtitle><description>To assess the efficacy of combined therapy involving bland transarterial embolization using gelatin sponge particles (bland GS-TAE) followed by transarterial chemoembolization using lipiodol mixed with anticancer agents and GS particles (Lip-TACE) to reduce the adverse events and increase the therapeutic effect of Lip-TACE in the treatment of huge (≥10 cm) hepatocellular carcinoma (HCC). Twenty-one consecutive patients with huge HCCs (≥10 cm in diameter) were enrolled in this study. First, bland GS-TAE was performed to reduce the tumor volume, and then Lip-TACE was performed to control the remaining tumor at intervals of around three weeks. Tumor response, survival, and adverse events of this combined therapy were assessed. The tumor response was assessed three months after combined TACE, with complete response in 38.1% and partial response in 57.1% of cases. Severe adverse events were seen in two patients, acute cholecystitis and tumor rupture. The median survival time was 2.7 years, and the one-, two-, three-, and five-year overall survival rates were 76.2%, 66.7%, 42.9%, and 25.0%, respectively. Combined therapy involving bland GS-TAE followed by Lip-TACE can be performed safety and may improve survival in patients with huge HCCs.</description><subject>bland embolization</subject><subject>huge hepatocellular carcinoma</subject><subject>transarterial chemoembolization</subject><issn>1364-5706</issn><issn>1365-2931</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kLtOHDEUhi0EAgJ5hCCXUAzxZTyXDoSAICGlgdo640vWyB4v9ozQpkrLg_BiPAkz2QWJhuoc_frORR9CPyg5paQhPymvSlGT6pQRNkU1E6IhW2h_ykXBWk63__dlMUN76FvOD4QwKnizi_Y4I5yWdbmP_KW1ToFa4WixiqFzvdG489BrbEIXvfsLg4s9ngO1MCF-Sm1MeDH-Mfj49fmFktd_zyqc4IVZwhCV8X70kLCCpFwfAxyiHQs-m--beoDury7vLn4Vt7-vby7ObwslBBuKznIgnFjVGaZ0W2sh2rqCmtWmaZmuGj5933RtBbQyQvBaGwINNbahoKni_AAdr_cuU3wcTR5kcHl-B3oTxywZF6zijJVsQsUaVSnmnIyVy-QCpJWkRM6i5btoOYuWG9HT3NHmxNgFoz-m3s1OwNkacP0kKcBTTF7LAVY-JpugVy5L_vWNN3mdjyY</recordid><startdate>20200207</startdate><enddate>20200207</enddate><creator>Hidaka, Teruyuki</creator><creator>Anai, Hiroshi</creator><creator>Sakaguchi, Hiroshi</creator><creator>Sueyoshi, Satoru</creator><creator>Tanaka, Toshihiro</creator><creator>Yamamoto, Kiyosei</creator><creator>Morimoto, Kengo</creator><creator>Nishiofuku, Hideyuki</creator><creator>Maeda, Shinsaku</creator><creator>Nagata, Takeshi</creator><creator>Kichikawa, Kimihiko</creator><general>Taylor &amp; Francis</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20200207</creationdate><title>Efficacy of combined bland embolization and chemoembolization for huge (≥10 cm) hepatocellular carcinoma</title><author>Hidaka, Teruyuki ; Anai, Hiroshi ; Sakaguchi, Hiroshi ; Sueyoshi, Satoru ; Tanaka, Toshihiro ; Yamamoto, Kiyosei ; Morimoto, Kengo ; Nishiofuku, Hideyuki ; Maeda, Shinsaku ; Nagata, Takeshi ; Kichikawa, Kimihiko</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c552t-bf3a030fcbe2cd97d55976a727e892d6830318b96a16e5537de0a81ef81ad1c33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>bland embolization</topic><topic>huge hepatocellular carcinoma</topic><topic>transarterial chemoembolization</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hidaka, Teruyuki</creatorcontrib><creatorcontrib>Anai, Hiroshi</creatorcontrib><creatorcontrib>Sakaguchi, Hiroshi</creatorcontrib><creatorcontrib>Sueyoshi, Satoru</creatorcontrib><creatorcontrib>Tanaka, Toshihiro</creatorcontrib><creatorcontrib>Yamamoto, Kiyosei</creatorcontrib><creatorcontrib>Morimoto, Kengo</creatorcontrib><creatorcontrib>Nishiofuku, Hideyuki</creatorcontrib><creatorcontrib>Maeda, Shinsaku</creatorcontrib><creatorcontrib>Nagata, Takeshi</creatorcontrib><creatorcontrib>Kichikawa, Kimihiko</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Minimally invasive therapy and allied technologies</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hidaka, Teruyuki</au><au>Anai, Hiroshi</au><au>Sakaguchi, Hiroshi</au><au>Sueyoshi, Satoru</au><au>Tanaka, Toshihiro</au><au>Yamamoto, Kiyosei</au><au>Morimoto, Kengo</au><au>Nishiofuku, Hideyuki</au><au>Maeda, Shinsaku</au><au>Nagata, Takeshi</au><au>Kichikawa, Kimihiko</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy of combined bland embolization and chemoembolization for huge (≥10 cm) hepatocellular carcinoma</atitle><jtitle>Minimally invasive therapy and allied technologies</jtitle><addtitle>Minim Invasive Ther Allied Technol</addtitle><date>2020-02-07</date><risdate>2020</risdate><volume>30</volume><issue>4</issue><spage>221</spage><epage>228</epage><pages>221-228</pages><issn>1364-5706</issn><eissn>1365-2931</eissn><abstract>To assess the efficacy of combined therapy involving bland transarterial embolization using gelatin sponge particles (bland GS-TAE) followed by transarterial chemoembolization using lipiodol mixed with anticancer agents and GS particles (Lip-TACE) to reduce the adverse events and increase the therapeutic effect of Lip-TACE in the treatment of huge (≥10 cm) hepatocellular carcinoma (HCC). Twenty-one consecutive patients with huge HCCs (≥10 cm in diameter) were enrolled in this study. First, bland GS-TAE was performed to reduce the tumor volume, and then Lip-TACE was performed to control the remaining tumor at intervals of around three weeks. Tumor response, survival, and adverse events of this combined therapy were assessed. The tumor response was assessed three months after combined TACE, with complete response in 38.1% and partial response in 57.1% of cases. Severe adverse events were seen in two patients, acute cholecystitis and tumor rupture. The median survival time was 2.7 years, and the one-, two-, three-, and five-year overall survival rates were 76.2%, 66.7%, 42.9%, and 25.0%, respectively. Combined therapy involving bland GS-TAE followed by Lip-TACE can be performed safety and may improve survival in patients with huge HCCs.</abstract><cop>England</cop><pub>Taylor &amp; Francis</pub><pmid>32031474</pmid><doi>10.1080/13645706.2020.1725580</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1364-5706
ispartof Minimally invasive therapy and allied technologies, 2020-02, Vol.30 (4), p.221-228
issn 1364-5706
1365-2931
language eng
recordid cdi_proquest_miscellaneous_2352632242
source Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)
subjects bland embolization
huge hepatocellular carcinoma
transarterial chemoembolization
title Efficacy of combined bland embolization and chemoembolization for huge (≥10 cm) hepatocellular carcinoma
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-24T12%3A30%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_infor&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20of%20combined%20bland%20embolization%20and%20chemoembolization%20for%20huge%20(%E2%89%A510%E2%80%89cm)%20hepatocellular%20carcinoma&rft.jtitle=Minimally%20invasive%20therapy%20and%20allied%20technologies&rft.au=Hidaka,%20Teruyuki&rft.date=2020-02-07&rft.volume=30&rft.issue=4&rft.spage=221&rft.epage=228&rft.pages=221-228&rft.issn=1364-5706&rft.eissn=1365-2931&rft_id=info:doi/10.1080/13645706.2020.1725580&rft_dat=%3Cproquest_infor%3E2352632242%3C/proquest_infor%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c552t-bf3a030fcbe2cd97d55976a727e892d6830318b96a16e5537de0a81ef81ad1c33%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2352632242&rft_id=info:pmid/32031474&rfr_iscdi=true